Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
In vivo imaging of fibrillar β-amyloid deposits may assist clinical diagnosis of Alzheimer’s disease (AD), aid treatment selection for patients, assist clinical trials of therapeutic drugs through subject selection, and be used as an outcome measure. A recent phase III trial of [ 18 F]flutemetamol positron emission tomography (PET) imaging in 106 end-of-life subjects demonstrated the ability to identify fibrillar β-amyloid by comparing in vivo PET to post-mortem histopathology. Post-mortem analyses demonstrated a broad and continuous spectrum of β-amyloid pathology in AD and other dementing and non-dementing disease groups. The GE067-026 trial demonstrated 91% sensitivity and 90% specificity of [ 18 F]flutemetamol PET by majority read for the presence of moderate or frequent plaques. The probability of an abnormal [ 18 F]flutemetamol scan increased with neocortical plaque density and AD diagnosis. All dementia cases with non-AD neurodegenerative diseases and those without histopathological features of β-amyloid deposits were [ 18 F]flutemetamol negative. Majority PET assessments accurately reflected the amyloid plaque burden in 90% of cases. However, ten cases demonstrated a mismatch between PET image interpretations and post-mortem findings. Although tracer retention was best associated with amyloid in neuritic plaques, amyloid in diffuse plaques and cerebral amyloid angiopathy best explain three [ 18 F]flutemetamol positive cases with mismatched (sparse) neuritic plaque burden. Advanced cortical atrophy was associated with the seven false negative [ 18 F]flutemetamol images. The interpretation of images from pathologically equivocal cases was associated with low reader confidence and inter-reader agreement. Our results support that amyloid in neuritic plaque burden is the primary form of β-amyloid pathology detectable with [ 18 F]flutemetamol PET imaging. ClinicalTrials.gov NCT01165554. Registered June 21, 2010; NCT02090855. Registered March 11, 2014.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Measuring nominal scale agreement among many raters.
Fleiss, J. L. (1971) · Psychological Bulletin · doi:10.1037/h0031619 · Cited by 8,733 · cited 1×
“The Fleiss coefficient Pi was used to measure inter-reader agreement [Pi = 1/n(n-1)*(A 2 +N(2)-n), where n is the number of readers, A is the number calling the case abnormal, and N is the number of readers calling the case negative] [18].”
MethodPhases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490 · cited 10×
“AD neuropathologic changes were also categorised post-hoc according to the more recent NIA-Alzheimer’s Association criteria (NIA-AA) [25] using amyloid phase [58], Braak NFT stage and CERAD neuritic plaque score, collected above, as these criteria were published after trial initiation.”
BackgroundMethodResultInfluentialSelf-citationSecond consensus statement on the diagnosis of multiple system atrophy
Gilman, S., Wenning, G. K., Low, P. A., Brooks, D. J., Mathias, C. J., Trojanowski, J. Q., Wood, N. W., Colosimo, C., Dürr, A., Fowler, C. J., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000324625.00404.15 · Cited by 3,140 · cited 1×
“degeneration (Picks Disease) [29], dementia with Lewy bodies [42], multiple system atrophy [22], and progressive supranuclear palsy [23, 40].”
BackgroundHyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092 · cited 14×
“Interestingly, this case would be considered as having intermediate AD neuropathology changes if using the more recent National Institute on Aging-Alzheimer's Association (NIA-AA) diagnostic criteria [25].”
BackgroundMethodInfluentialSelf-citationFrequency of Stages of Alzheimer-Related Lesions in Different Age Categories
Braak, H., & Braak, E. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00056-0 · Cited by 1,656
HYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542
Primary age-related tauopathy (PART): a common pathology associated with human aging
Crary, J. F., Trojanowski, J. Q., Schneider, J. A., Abisambra, J. F., Abner, E. L., Alafuzoff, I., Arnold, S. E., Attems, J., Beach, T. G., Bigio, E. H., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1349-0 · Cited by 1,467 · cited 1×
“It should be noted that subsequent to the trial additional guidelines and diagnostic criteria for AD [25] and primary age-related tauopathy [13] have been published.”
BackgroundSelf-citationUse of Florbetapir-PET for Imaging β-Amyloid Pathology
Clark, C. M. (2011) · JAMA · doi:10.1001/jama.2010.2008 · Cited by 1,117
Beach, T. G., Monsell, S. E., Phillips, L. E., & Kukull, W. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31824b211b · Cited by 1,103 · cited 1×
“The relatively modest accuracy of a clinical diagnosis of Alzheimer’s disease (AD) when compared to the definitive neuropathological findings at autopsy [4] demonstrates a current unmet need to detect the neuropathological hallmarks of AD (β-amyloid plaques and neurofibrillary tangles) in life.”
BackgroundSelf-citation
Cited by
Lane, C. A., Hardy, J., & Schott, J. M. (2018) · European Journal of Neurology · doi:10.1111/ene.13439 · Cited by 2,616
Microglial activation correlates in vivo with both tau and amyloid in Alzheimer’s disease
Dani, M., Wood, M., Mizoguchi, R., Fan, Z., Walker, Z., Morgan, R., Hinz, R., Biju, M., Kuruvilla, T., Brooks, D. J., et al. (2018) · Brain · doi:10.1093/brain/awy188 · Cited by 270
CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease
Horie, K., Salvadó, G., Barthélemy, N. R., Janelidze, S., Li, Y., He, Y., Saef, B., Chen, C. D., Jiang, H., Strandberg, O., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02443-z · Cited by 249
Staging β -Amyloid Pathology With Amyloid Positron Emission Tomography
Mattsson, N., Palmqvist, S., Stomrud, E., Vogel, J., & Hansson, O. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.2214 · Cited by 237
Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers
for the Alzheimer’s Disease Neuroimaging Initiative, F. T. A. S., Salvadó, G., Molinuevo, J. L., Brugulat-Serrat, A., Falcon, C., Grau-Rivera, O., Suárez-Calvet, M., Pavia, J., Niñerola-Baizán, A., Perissinotti, A., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0478-z · Cited by 195
Metadata
- Authors
- Ikonomovic, M. D., Buckley, C. J., Heurling, K., Sherwin, P., Jones, P. A., Zanette, M., Mathis, C. A., Klunk, W. E., Chakrabarty, A., Ironside, J., Ismail, A., Smith, C., Thal, D. R., Beach, T. G., Farrar, G., & Smith, A. P. L.
- Venue
- Acta Neuropathologica Communications
- Published
- 2016-12
- Volume
- 4
- Issue
- 1
- Pages
- 130-130
- ISSN
- 2051-5960 (ISSN-L)
- OpenAlex
- W2564633427
- Cited by
- 98
- References
- 26
- FWCI
- 7.50
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection. https://app.cochat.ai/papers/10.1186/s40478-016-0399-z
- The paper
- Ikonomovic, M. D., Buckley, C. J., Heurling, K., Sherwin, P., Jones, P. A., Zanette, M., Mathis, C. A., Klunk, W. E., Chakrabarty, A., Ironside, J., Ismail, A., Smith, C., Thal, D. R., Beach, T. G., Farrar, G., & Smith, A. P. L. (2016). Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection. Acta Neuropathologica Communications. https://doi.org/10.1186/s40478-016-0399-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.